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Abstract
In  1993,  the  first  superoxide  dismutase  1  (SOD1)  mutation in  amyotrophic  lateral
sclerosis (ALS) patients has been described by Rosen et al. successively, the scientific
literature focused on the role of SOD1 in the pathogenesis of ALS. While a clear genetic
scenario  has  been presented,  heterogeneous  data  have  been formulated regarding
transcriptional and post-transcriptional regulation of SOD1 so far. In particular, the
dilemma concerns the SOD1 protein expression, in the direction of a loss of function of
the wild-type SOD1 or a toxic gain of function of the altered SOD1, both in FALS
(mutant-SOD1)  and  in  SALS  (misfolded-SOD1).  In  this  chapter,  we  focus  on  the
evolution of scientific knowledge about SOD1 protein in ALS patients, reviewing in
detail  the  results  obtained  using  peripheral  blood  cells  in  this  research  field.  To
conclude, we propose a brief summary of the described clinical correlation and discuss
the possible SOD1 implication as a biomarker of ALS.
Keywords: trascriptional regulation, post-trascriptional regulation, amyotrophic later‐
al sclerosis (ALS), superoxide dismutase 1 (SOD1), biomarkers, protein aggregation
1. Introduction
Cu/Zn superoxide dismutase (SOD1) is a 32-KDa homodimeric enzyme that assumes a pivotal
role in the scavenging process of the toxic superoxide radicals in the cells [1]. SOD1 is highly
expressed in the cytoplasm, but in the 1980s, Chang and colleagues identified SOD1 in other
sub-cellular compartments, such as nucleus, lysosomes, and mitochondria [2]. In the 1990s, the
scientific literature focused on the genetic and biochemical characterization of SOD1, and in
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1993, Rosen et al. [3] described the first SOD1 gene mutation associated with amyotrophic lateral
sclerosis (ALS) [3]. ALS is an adult-onset neurodegenerative disease that affects selectively
cortical, bulbar, and spinal motor neurons, leading invariably to a fatal prognosis. The majori‐
ty of ALS cases (90–95%) are sporadic (SALS), whereas 5–10% are familial (FALS), with genetic
mutations dominantly inherited. Among these, more than 150 SOD1 mutations have been
reported that are responsible for 20% of FALS, but also 1% of SALS [4]. During the last 20 years,
many studies were focused on SOD1 protein in the pathogenesis of ALS, both for FALS and for
SALS. Hitherto, some aspects remain unclear: (1) SOD1 alterations give selective loss of motor
neurons, even though the enzyme is ubiquitous in every cell; (2) mutations confer SOD1 enzyme’s
loss of function reducing antioxidant activity but, in some way, mutated enzyme can acquire
toxicity; (3) the ALS phenotype doesn’t reflect the common presentation of the loss-of-function-
related diseases, in terms of age of onset, clinical spreading, and evolution. In this chapter, we
would like to pass through the recent understandings about SOD1 protein in the pathogene‐
sis of ALS, in particular focusing on its aggregation in peripheral blood cells and its transcrip‐
tional/post-transcriptional regulation.
2. SOD1 and ALS models
2.1. Investigating SOD1-mediated pathogenesis in different cellular models
The SOD1 gene is located on chromosome 21q22.11 (Figure 1), and more than 150 mutations
have been discovered since 1993, all of them proving to be causative of ALS.
Figure 1. Structure of SOD1 gene.
The discovery of SOD1 mutations in ALS patients allowed the possibility to create transgenic
models of the pathology. As familial and sporadic forms of ALS demonstrated to be clinically
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undistinguishable, in the 1990s SOD1-G93A mouse model was realized and allowed for an in-
depth stepwise exploration of the neurodegenerative process occurring in ALS.
Conversely, a different scientific approach applies to the understanding of the mechanisms of
disease directly in humans. The major limitation is represented indeed by the scarce availa‐
bility of samples in sufficient quality and high relevance for ALS [5], being spinal cord, brain
stem, motor cortex, and muscles as the primary targets of the disease process. The first
criticality towards the use of post-mortem tissues is that they represent the end stage of the
disease. In second place, the quality of tissues may be compromised by the interval after death
and protein alterations occurring independently of ALS that may affect the specificity of the
finding [6]. Thus, the proximity of the tissue to the disease pathogenic process, and thus the
possibility to uncover a biologically meaningful, highly specific, marker of disease progression,
is at the expenses of the accessibility of the given tissues and the opportunity to sample them
more than once.
Regarding muscle biopsy, one of the advantages is the shorter processing time compared to
post-mortem tissues, but at present there are no sufficient data to support this method of
analysis. The presence of neurogenic atrophy is peculiar, but non-disease specific, of ALS.
Besides that, these alterations are known to occur late during disease course and they could
be measured less invasively with electrodiagnostic testing [6, 7]. As a last consideration, most
of the changes observed at the muscle sample are not acknowledged to belong to some specific
biochemical pathways or to be just a mere consequence of the denervation process [7, 8].
Because of the large feasibility for repeated testing and the presence of standard operating
procedures, blood and cerebrospinal fluid (CSF) have become the most popular biofluids
deployed for ALS research [7]. Indeed, these features allow for longitudinal sample collection
at high quality and minimal inter-assay differences. On the contrary, both matrices will contain
only diluted concentrations of the protein of interest, which can turn into an advantage if the
disease process for which the biomarker is released occurs at multiple scattered points within
central nervous system (CNS) impossible to be sampled [5]. Furthermore, there is a massive
dynamic range of proteins within these two fluids that is present at several orders of magnitude
above the candidate biomarkers and could interfere with their detection. CSF is the closest of
the two to the CNS compartment, and thus it is more likely to reflect pathological processes
occurring within it; in contrast, blood-brain barrier is narrowing the amount of biomarkers
possibly circulating in serum or plasma, even though recent studies revealed an impaired
function of the latter [9]. On the clinical ground, lumbar puncture is definitely more invasive
than venopuncture and subject to an increasing number of variables, such as the possibility of
contamination with blood at the side of the puncture and the heterogeneity of sampled volume.
Serum or plasma collection is much more accessible, and patients are more compliant to
multiple sampling [10]. Both these biofluids can be influenced by multiple systemic phenom‐
ena at the time, such as inflammation, dysmetabolism, or damage at the neuromuscular level,
which could increase the sensitivity and also act as confounding factors in the interpretation
of the source of these candidate biomarkers [5].
Considering the ubiquitous nature of SOD1, and the aforementioned privilege of multiple
blood sampling for the research of this highly progressive, severely disabling disease, SOD1-
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mediated pathogenesis of ALS has been extensively investigated through the use of blood cells.
Moreover, damaged metabolism of lymphocytes was studied in other neurodegenerative
diseases, confirming the pertinence of these cells as an appealing tool in understanding the
pathogenesis of neurodegeneration [11].
2.2. SOD1 aggregation
In the 1990s, early studies on erythrocytes and lymphocytes of mutated SOD1 FALS proved
decreased concentrations and altered the activity of the enzyme years before the onset of
pathology [12–14]. However, this modification was restricted to mutated SOD1 ALS patients.
In the last years, a growing body of studies showed peripheral blood mononuclear cells
(PBMC) of ALS patients and, regardless of the genetic basis, displayed distinctive traits
compared to healthy and neurological controls. These alterations mainly concern an aberrant
antioxidant response reflected by mitochondrial and calcium-dysregulated metabolism [15]
and decreased Bcl-2 and SOD1 expression in peripheral lymphocytes [16, 17] accompanied by
the inability to down-regulate these proteins under oxidative stress [16].
In 2010, while investigating mRNA SOD1 expression in lymphocytes from SALS patients as a
potential explanation for the decreased levels of SOD1 protein, Gagliardi et al. [18] found that
there is increased transcription of SOD1 in the lymphocytes of SALS (compared to healthy and
neurological controls). Similar enhanced expression of SOD1 mRNA was found in selected
sections of motor spinal cord and brain stem of ALS patients as well, though this phenomenon
was absent from cerebellum and non-motor areas of the same patients. At the same time, SOD1
protein levels in the disease-affected tissues from SALS patients did not show any statistical
difference compared to controls [18]. These observations imply that SOD1 increased tran‐
scription and the decreased protein expressions are disease-specific cellular events, which are
apparent, and thus possible to study, at peripheral level. This gap of knowledge between
mRNA and protein levels of SOD1 in ALS patients opened a new scenario, in which the study
of sub-cellular compartments was pivotal. Initially, a conformational modified SOD1 was
observed both in SALS and FALS (misfolded SOD1 and mutant SOD1 respectively), instead
of wild-type SOD1 [19]. The pathogenic role of misfolded SOD1 was first hypothesized by
Gruzman et al. [20], and additional evidence was subsequently provided by other authors [21,
22]. Specifically, Forsberg et al. [22–23] found similar misfolded SOD1-Bcl2 aggregations in
SALS and Pasinelli et al. [24] described it in FALS (mutant SOD1-Bcl2) [23, 24]. Given that, the
hypothesis was that wild-type SOD1, under many environmental triggers, became misfolded
SOD1 with reduced antioxidant activity (loss of function) and acquired toxic property as
mutant SOD1 has [25]. Cereda and co-workers [26] demonstrated a bigger total amount of
SOD1 in PBMCs of SALS patients than in cells of healthy controls or Alzheimer patients [26].
Curiously, the SOD1 distribution allowed to distinguish two different categories of patients:
the first group had perinuclear SOD1 aggregates and the second one higher nuclear SOD1. In
addition, Cereda [26] observed that patients with more perinuclear SOD1 expressed a major
amount of insoluble proteins while the other group, characterized by predominant nuclear
SOD1, had especially soluble fractions. Eventually, the authors tested whether these findings
had clinical correlates (see Table 1 for general characteristics of patient cohort). Indeed, longer
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disease durations from onset to time of sampling and from onset to last visit were found in
patients with larger amount of soluble nuclear SOD1 (Figure 2, A, B, p < 0.05). In contrast, no
significant correlation was observed between nuclear SOD1 ratio and duration from time of
sampling to last visit (data not shown). At the same time, a mild increasing trend was found
between patients with high nuclear SOD1 and early ALS stage as assessed by ALSFRS-r score
at sampling (Figure 2C, p > 0.05). If these data were confirmed in larger cohorts followed-up
longitudinally and employing specific antibodies against misfolded SOD1, this hallmark could
be a useful biomarker for stratifying patients according to the pace of progression of the
disease.
Clinimetrics Patients
Gender
Female/male
7/12
Age of onset (years)
Mean ± SEM
61.2 ± 2.75
Diagnostic latency (months)
Mean ± SEM
14.8 ± 4.38
Site of onset
Bulbar/limb
9/10
Disease duration at sampling (months)
Mean ± SEM
25.4 ± 7.26
ALS-FRS_r at visit
Mean ± SEM
38.7 ± 2.11
Progression rate at baseline (PRB)
Mean ± SEM
0.55 ± 0.23
Disease duration from baseline to last visit/death (months)
Mean ± SEM
50.2 ± 11.18
UMN/LMN dominance
Exclusive UMN/dominant UMN/both UMN-LMN/dominant LMN/exclusive LMN
1/1/6/6/5
Cognitive involvement
Yes/no
3/16
Respiratory involvement
Yes/no
11/8
SOD1 localization
High nuclear fraction/low nuclear fraction
13/6
PRB, progression rate at baseline that is calculated as (48-ALSFRS-r score at baseline)/timeline between onset of disease
and baseline visit; PRB values <0.5 between 0.5–1 and >1 imply patients are slow, intermediate, or fast progressors,
respectively.
Table 1. Characteristics of patients.
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Figure 2. Correlations between nuclear SOD1 and clinimetrics.
Furthermore, this mechanism of pathogenesis could be present in other neurodegenerative
disease (such as Parkinson’s disease, Alzheimer dementia) and in different conditions, such
as prion disease or amyloidosis, possibly unifying all these pathologies under the term
‘proteinopathies’, where an aberrantly fold protein becomes the ‘seeding template’ for other
normally constituted proteins to misfold and aggregate in intra- and extra-neuronal beta-
strand structures, conferring toxicity to selected populations of neurons. Interestingly, recent
studies have attempted to unravel the mechanism of spreading the abnormally fold proteins
from one neuron to the other. One of the main hypothesis scientific literature is testing now is
that extracellular vesicles, which are small plasma membrane-derived spheres containing
RNAs, enzymes, signal transduction factors, etc., and acting as transporters of these substances
[27], may be the vehicles of toxic proteins, explaining how the disease seeds from very distant
sites to others with certain degrees of selectivity.
3. SOD1 protein
3.1. Transcriptional regulation
SOD1 has high and ubiquitous expression; its induction is fine-tuned and modulated by
complex intracellular events which probably engage multiple positive and negative regulatory
elements acting altogether [28]. Different transcriptional factors were involved in SOD1
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constitutive and inducible expression. Among these, the C/EBPs (CCAAT/enhancer-binding
proteins) have been demonstrated to be necessary for SOD1 constitutive expression. C/EBP
consensus element partially overlaps the Sp1/Egr1 sequence, suggesting that these transcrip‐
tion factors may act in the control of SOD1 gene expression regulation [29]. Furthermore, also
the transcription factor CCAAT/enhancer-binding protein delta is involved in the regulation
of human SOD1 transcription [30]: In particular, it enhances SOD1 mRNA expression in
cisplatin-treated human urothelial carcinoma cell line (NTUB1) via a direct promoter transac‐
tivation. The over-expression of Sp1 (Specificity Protein 1) enhances SOD1 basal promoter
activity [31].
It has also been demonstrated that cytokines and stress signals (radiation, injury, and oxidative
or mechanical stress) can induce the expression of early growth response-1 (Egr1), a nuclear
phosphoprotein regulator of transcription. Minc and co-workers [32] demonstrated that SOD1
mRNA level rapidly increased after phorbol-12-myristate-13-acetate (PMA) treatment in HeLa
cells, and the region between nucleotides −59 and −48 presents noncanonical consensus
recognition sequences for Sp1 and Egr1, and it is bound by Egr1 in response to PMA exposure.
It has been demonstrated that activating protein 1 (AP1) represses SOD1 transcription by
sequestrating essential coactivators such as Sp1 [31]. Furthermore, neuronal nitric oxide
synthase (nNOS) over-expression causes SOD1 down-regulation of mRNA, protein, and
activity levels [33], and that this seems to be caused by both the decreased binding of Sp1 to
SOD1 promoter, caused by nNOS interaction with Sp1, and a concomitant increased binding
activity of AP1 to the same site.
An increased expression of SOD1 mRNA and protein was reported after the exposure of
human HepG2 and HeLa cells to the 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD), an environ‐
mental contaminant and interacting with aryl hydrocarbon receptor (AHR) [34]. They also
identified the presence of a xenobiotic responsive element (XRE) in the 5′ -flanking region of
human SOD1 gene (between −255 and −238 from the transcription start site), which is respon‐
sible for the induction by TCDD. A thyroid hormone (TR) inhibitory element was identified
between −157 and +17 of the human SOD1 promoter, and T3 exposure reverses the induction
of SOD1 transcription caused by the ROS-producing paraquat and PMA agents [35]. Also,
SOD1 promoter is significantly up-regulated by unliganded TRs.
NF-κB was one of the first transcription factors shown redox regulated [36, 37]. Moreover, cell
treatment with H2O2 triggers the PI3K/Akt cascade, which participates in NF-κB activation and
in consequent SOD1 transcriptional induction. Thus, a p65-NF-κB-binding site in the human
SOD1 promoter (GGTAAGTCCC) was identified, and Akt-activated NF-κB presents an
increased binding to this sequence, mediating the up-regulation of SOD1 expression [38].
Dell’Orco et al. [39] investigated if SOD1 over-expression could be related to transcriptional
regulation; in particular, they consider the relationship between the nuclear factor E2-related
factor 2 (Nrf2) transcription factor and SOD1 promoter [39]. The dissociation from Keap1 is a
prerequisite for Nrf2 translocation to the nucleus. The activated Nrf2 re-localizes into the
nucleus where it binds to ARE=adenine/uracil-rich element sequences and activates the
expression of different cytoprotective target genes. Moreover, an ARE-binding element,
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located between −356 and −330 from the transcription start site and targeted by Nrf2, has been
identified in SOD1 promoter [40]. By means of a probe harbouring the SOD1 ARE element, we
reported the presence of a dynamic protein-DNA complex, which suggested that after H2O2
treatment, the cis-acting ARE sequence in SOD1 promoter plays an important role by recruiting
multiple TFs and/or cofactors, probably co-operating to modulate SOD1 mRNA induction
under oxidative stress. ChIP assay followed by qRT-PCR with primers designed to flank the
ARE element in SOD1 promoter showed that Nrf2 occupancy at the ARE elements in SOD1
promoter did not change after H2O2 treatment. We also reported a minimal increased associ‐
ation at the ARE element in NQO1 gene, a well-known Nrf2 gene target, thus indicating that
Nrf2 cannot gain access to SOD1 5′-flanking region in a native chromatin context. SOD1 mRNA
up-regulation in response to H2O2 oxidative treatment might indeed be ascribed to the
involvement of other transcriptional factors. These data suggested that SOD1 promoter is not
a canonical downstream target of the Nrf2 regulatory network and that Nrf2 may act as a
‘constitutive’ TF, binding to SOD1 ARE sequence even without stimulus, while H2O2 treatment
could induce changes in the chromatin conformation with consequent changes in the rela‐
tionship between the different TFs. In regard to SOD1 gene, it has been wrongly considered a
housekeeping gene; however, its inducible transcription is finely regulated by cis-acting
sequences and the corresponding transactive factors [39].
3.2. Post-transcriptional regulation
Until now, post-transcriptional control mechanisms of SOD1 expression are still unexplored;
nevertheless, post-transcriptional control represents a specific and punctual regulatory
mechanism for gene expression which can easily modify protein levels in response to extrac‐
ellular stimuli [41, 42]. Variations in gene expression are often the result of synergy between
transcriptional and post-transcriptional regulatory mechanisms [28]. Very few data on post-
transcriptional regulation of SOD1 have been reported so far. Two species of SOD1 mRNA
with different 3′UTR lengths which produce in vitro different quantities of SOD1 protein have
been identified. Kilk and colleagues [43] reported that the ability of long mRNA to produce
more SOD1 enzyme seems to be related to specific sequences located in the 3′UTR; moreover,
they identified the presence of AREs in this region (AUUUA, CUUUA, AUUUG, GUUUUA,
AUUUU, and AUUUC). In general, AREs represent the docking sites for different RNA-
binding proteins (RBPs), which can affect the metabolism of the target transcripts [44]. Among
ARE-binding RBPs, ELAV (or Hu) proteins play a critical role [45]; ELAV family comprises
the neuron-specific members HuB, HuC, and HuD [46] and the ubiquitously expressed HuR.
ELAV proteins act primarily as positive regulators of gene expression; they can increase the
stability and/or translation of target mRNAs whose proteins have fundamental cellular
functions.
Given the lack of data on this issue in ALS pathogenesis, Cereda’s group [26] focused its
attention on the modulation of SOD1 mRNA levels by post-transcriptional mechanisms, in
particular via ELAV proteins. Considering that oxidative stress plays a critical role in sporadic
ALS, and that it is a trigger of ELAV activation, by treating human neuroblastoma SH-SY5Y
cells with 1 mM H2O2, a significant up-regulation of SOD1 mRNA levels was reported [47].
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Milani and collaborators [47] also analysed the 3′UTR region of SOD1 mRNA and, by means
a bioinformatics analysis, they identified within SOD1 3′UTR primary sequence the presence
of AREs that are putative ELAV-binding sites. These data were consistent with the results
reported by Lopez de Silanes and colleagues [48]; REMSA and immunoprecipitation coupled
with real-time qPCR experiments demonstrated that the recombinant HuR protein bound
specifically and directly to the ARE-bearing probe of SOD1. In parallel, ELAV accumulates in
the cytoplasm; this intracellular relocation is in line with the role of ELAV/HuR as a nuclear-
cytoplasmic shuttling protein. Indeed, ELAV’s influence on target mRNAs depends on its
localization in the cytoplasm, where these proteins stabilize target mRNAs and regulate their
translation [49]. Taken together, these data seem to indicate that oxidative stress promotes
SOD1 induction probably mediated by ELAV-dependent mechanisms. Moreover, the kinase-
triggered phosphorylation of ELAV/HuR is crucial for the modulation of its function and
allows it to associate extracellular signals to specific post-transcriptional events elicited by this
RBP [50, 51]. Finally, Milani and co-authors [47] also reported an enhanced perinuclear and
cytoplasmic expression of ELAV in the cerebral motor cortex of SALS patients compared to
healthy subjects, suggesting that the up-regulated RBP proteins may be more available and
massively enrolled in the positive regulation of target mRNAs, such as SOD1. Remarkably,
positivity for cytoplasmic ELAV was paralleled by increased levels of both SOD1 mRNA and
protein [47].
SOD1 post-transcriptional regulation may also be mediated by microRNAs (miRNAs).
miRNAs are small non-protein-coding RNAs, which act as key post-transcriptional regulators
of gene expression by base pairing to the 3′UTR of the target mRNAs, causing translational
silencing and mRNA decay [52, 53], as it was reported for miR-377 in human and mouse
mesangial cells which diminished SOD1 protein levels [54].
In consideration of all these findings, we can conclude that the increase in SOD1 gene expres‐
sion is the consequence of an intricate process related both to the activation of a transcriptional
mechanism involving Pol II, and also other mechanisms such as chromatin changes and
epigenetic variations, mRNA, and protein stabilization.
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